BNB Plus (BNBX) Registration filing summary

Company overview and business model

• Operates as a digital asset treasury company, focusing on BNB (Binance Coin) as its primary reserve asset and leveraging DeFi opportunities for yield generation.

• Also commercializes proprietary nucleic acid production solutions for biopharmaceutical and diagnostics markets through its subsidiary LineaRx.

• Strategic shift in 2025 to prioritize BNB-focused treasury operations, with significant restructuring and workforce reductions to align resources.

• Holds BNB directly and via OBNB Trust Units, with plans to further accumulate BNB and monetize trust units as needed.

Financial performance and metrics

• Fiscal year ended September 30, 2025: $2.1M in total revenues, $838.9K gross profit, and $16M operating loss.

• Six months ended March 31, 2026: $1.6M product revenues, $26.5K service revenues, $1.1M gross profit, and $25.3M operating loss, driven by digital asset fair value losses and consulting expenses.

• Significant impairment charge of $2.7M in 2025 related to acquired R&D assets.

• Cash and cash equivalents as of March 31, 2026: $949K; working capital: $1.2M.

• Accumulated deficit of $404.5M as of March 31, 2026.

Use of proceeds and capital allocation

• Proceeds from warrant exercises will be used to increase digital asset treasury holdings, primarily BNB.

• $300K from recent private placement allocated to strategic advisory engagement; remaining proceeds for strategic review and general corporate purposes.

• Excess proceeds contributed to DAT subsidiaries for further BNB accumulation.